Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENABLE-2: ELVN-001 vs Investigator-Selected TKI in CP-CML
NCT07905183Phase 3Not yet recruiting
- Sponsor
- Enliven Therapeutics
- Start
- Dec 2026
- Primary completion
- Dec 2028
01
Overview
A Phase 3 trial of relcobatinib in chronic myeloid leukemia (CML), sponsored by Enliven Therapeutics. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
relcobatinib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT07905183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07905183.